Obiltoxaximab, a powerful monoclonal antibody against protective antigen (PA), is crucial for preventing anthrax toxin assembly and subsequent cell intoxication. Its application extends to dose translation studies from animal models to humans in the context of inhalational anthrax research [1] [2].